Treatment of Primary Sjogren Syndrome With Rituximab A Randomized Trial
Treatment of Primary Sjogren Syndrome With Rituximab A Randomized Trial
复制标题
DOI：
10.7326/m13-1085
复制
发表时间：
2014-02-18
影响因子：
39.2
通讯作者：
Saraux, Alain
中科院分区：
文献类型：
--
作者：
Devauchelle-Pensec, Valerie;Mariette, Xavier;Saraux, Alain
背景资料：原发性干燥综合征（Primary Sjogren syndrome，pSS）是一种自身免疫性疾病，以眼、口干燥或全身性症状为特征。目的：评价利妥昔单抗治疗成人原发性干燥综合征（primary Sjogren syndrome，pSS）的疗效和危害。研究人员（药剂师除外）、研究者和患者对治疗组设盲。（ClinicalTrials.gov：NCT 00740948）地点：法国14所大学医院。患者：120例患者，4种视觉模拟量表（VAS）（总体疾病、疼痛、疲劳和干燥）中至少有2种评分为50 mm或更高，
Background: Primary Sjogren syndrome (pSS) is an autoimmune disorder characterized by ocular and oral dryness or systemic manifestations.Objective: To evaluate efficacy and harms of rituximab in adults with recent-onset or systemic pSS.Design: Randomized, placebo-controlled, parallel-group trial conducted between March 2008 and January 2011. Study personnel (except pharmacists), investigators, and patients were blinded to treatment group. (ClinicalTrials.gov: NCT00740948)Setting: 14 university hospitals in France.Patients: 120 patients with scores of 50 mm or greater on at least 2 of 4 visual analogue scales (VASs) (global disease, pain, fatigue, and dryness) and recent-onset (